Sofokast-Plus (Sofosbuvir 400 mg + Daclatasvir 60 mg)

Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in adults:

• Genotypes 1, 2, 3, 4, 5, and 6.
• Patients with or without cirrhosis (compensated).
• Patients coinfected with HIV-1.

Dosage: One tablet taken orally once daily.

Treatment Duration:

• 12 Weeks: Standard duration for non-cirrhotic patients.
• 24 Weeks: May be required for patients with decompensated cirrhosis (often combined with Ribavirin).

⚠️ Administration: Swallow the tablet whole. Do not crush or chew due to bitter taste. Can be taken with or without food.

🚫 CRITICAL INTERACTION: AMIODARONE.

Co-administration with Amiodarone is contraindicated due to the risk of severe symptomatic bradycardia (heart slowing) or fatal cardiac arrest.

Other Contraindications:

• Pregnancy and breastfeeding.
• Strong inducers of P-gp (e.g., Rifampin, St. John's Wort, Carbamazepine) – they reduce the drug's effectiveness.

Side effects are generally mild and manageable:

• Fatigue and Headache.
• Nausea.
• HBV Reactivation Warning: Hepatitis B virus reactivation has been reported in HCV/HBV coinfected patients. Screening for HBV is mandatory prior to therapy.